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Abstract
Background Angiotensin-converting enzyme (ACE) inhib-
itors reduce clinical symptoms and improve outcome in
patients with hypertension, heart failure, and stable coro-
nary artery disease (CAD) and are among the most
frequently used drugs in these patient groups. For hyper-
tension, treatment is guided by the level of blood pressure.
In the secondary prevention setting, there are no means of
guiding therapy. Prior attempts to target ACE-inhibitors to
those patients that are most likely to benefit have not been
successful, mainly due to the consistency in the treatment
effect in clinical subgroups. Still, for prolonged prophylac-
tic treatment with ACE-inhibitors it would be best to target
treatment to only those patients most likely to benefit,
which would considerably lower the number needed to treat
and increase cost-effectiveness. A new approach for such
“tailored-therapy” may be to integrate information on the
genetic variation between patients. Until now, pharmaco-
genetic research of the efficacy of ACE-inhibitor therapy in
CAD patients is still in a preliminary stage.
Methods The PERindopril GENEtic association study
(PERGENE) is a substudy of the EUROPA trial, a randomized
double-blind placebo-controlled multicentre clinical trial
which demonstrated a beneficial effect of the ACE-inhibitor
perindopril in reducing cardiovascular morbidity and mortal-
ity in 12.218 patients with stable coronary artery disease
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(mean follow-up 4.2 years). Blood tubes were received from
patients at the beginning of the EUROPA trial and buffy coats
were stored at −40°C at the central core laboratory. Candidate
genes were selected in the renin–angiotensin-system and
bradykinin pathways. Polymorphisms were selected based
on haplotype tagging principles using the HapMap
genome project, Seattle and other up-to-date genetic
database platforms to comprehensively cover all common
genetic variation within the genes. Selection also took into
consideration the functionality of SNP’s, location within
the gene (promoter) and existing relevant literature. The
main outcome measure of PERGENE is the effect of
genetic factors on the treatment benefit with ACE-
inhibitors. The size of this pharmacogenetic substudy
allows detection with a statistical power of 98% to detect
a difference in hazard ratios (treatment effect) of 20%
between genotypes with minor allele frequency of 0.20
(two-sided alpha 0.05).
Conclusion The PERGENE study is a large cardiovas-
cular pharmacogenetic study aimed to assess the
feasibility of pharmacogenetic profiling of the treatment
effect of ACE-inhibitor use with the perspective to
individualize treatment in patients with stable coronary
artery disease.
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Introduction
The efficacy of ACE-inhibitors to improve outcome has
been demonstrated by several large clinical trials in patients
with cardiovascular disease. These include post-myocardial
infarction (MI) patients, patients with asymptomatic left
ventricular systolic dysfunction, heart failure or a history of
cerebrovascular disease, and stable CAD patients with
preserved left ventricular function [1–7]. Currently, the
use of ACE inhibitors is recommended in guidelines on the
management of hypertension, stable CAD, MI, heart
failure, and in the prevention of the progression of renal
insufficiency in diabetes mellitus related kidney disease [8–
10]. The ACE-inhibitor perindopril has been extensively
studied in several large, controlled trials in a variety of
patient groups with different etiologies [7, 11–14]. Of these,
the EUROPA trial is noteworthy, as it is the only secondary
prevention study with perindopril in a stable CAD
population. ACE inhibitor research has also led to a better
understanding of pathophysiological processes and mal-
adaptive responses in the renin–angiotensin aldosterone
system (RAAS). In particular, several sub-studies of
EUROPA (including PERFECT, PERSPECTIVE and PER-
TINENT), have established that ACE inhibitors have
additional effects beyond the blood pressure reduction
alone such as the improvement of endothelial function,
improvement of the neuro-humoral balance, and reduction
of unfavorable remodeling of the coronary arteries [15–18].
For hypertension, treatment is guided by the level of
blood pressure. In the secondary prevention setting, there
are no means by which we can guide therapy. Many
patients need to be treated, and absolute benefits are
modest. It is not yet possible to predict in advance which
patients are to benefit most from treatment. Prior attempts
to target ACE-inhibitors to those patients who are most
likely to benefit have not been successful, mainly because
of the consistency in the treatment effect in clinically
relevant subgroups based on simple clinical characteristics
[19–21]. Treating only those patients who are most likely
to benefit would considerably lower the number needed to
treat and increase cost-effectiveness. A new approach to
“tailored-therapy” concerns cardiovascular pharmacoge-
netics which examine the genetic determinants of patients’
responses to cardiovascular drugs; in other words, under-
standing why some drugs work better for some patients
than others and why some patients are more likely to
experience serious side-effects than others. Many (if not
all) aspects of human physiology have genetic determi-
nants and could therefore be subject to pharmacogenetic
studies.
Several factors may be expected to play a dominant role
in determining the response of a patient to therapy. In
particular, in the case of ACE inhibition, genetic factors
within the RAS pathway are likely to affect its pharmaco-
dynamics and clinical efficacy. Genetic factors causing
differences in drug absorption and metabolic clearance are
also relevant. However, until now there are no strong leads
to explore this pharmaco-genetically since there are no
metabolic (CYP) genes linked specifically to ACE-inhib-
itors, although this might also be a relevant pathway to
investigate in future research.
In previous studies, several genetic polymorphisms in
RAAS genes have been associated with high blood pressure
levels or an increased cardiovascular risk [22, 23]. Nearly
all these studies focused at two polymorphisms, the ACE I/
D polymorphism and the M235T polymorphism in the
angiotensinogen gene. Because of limited power, due to
limited study sample size, results have been inconsistent
and the underlying questions not answered adequately.
With regard to interaction between genetic factors and
treatment response, the results are scarce. No prior studies
have been performed yet with ACE-inhibitors at a large
scale neither in a randomized setting nor in stable CAD
(one of the major indications of ACE-inhibitors). Another
important limitation of prior research in cardiovascular
pharmacogenetics is the investigation of one or two poly-
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morphisms within only one gene, thereby ignoring the well-
documented feedback mechanisms within the RAAS and
the fact that there are two angiotensin II receptors (AT1 and
AT2), which have counteracting effects also in humans. We
suggest that a more comprehensive coverage of genetic
variation in multiple RAAS genes is needed, by using a
correct haplotype approach. This is achieved by using the
latest information on genetic variation and linkage disequi-
librium patterns in the selection of haplotype-tagging SNP’s.
The PERGENE study aims at assessing the feasibility of
pharmacogenetic profiling of ACE-inhibitor therapy in
patients with stable CAD. We hypothesized that genetic
polymorphism in the RAAS and kininogen–kallikrein–
bradykinin pathways may influence the treatment effect
of ACE-inhibitors in patients with stable CAD. The
PERGENE study is unique in the field of pharmacogenetic
studies because of the large sample size, a randomized and
placebo-controlled design, and the availability of extensive
and accurate phenotypic data. Also, the extensive selection
of tagging SNP’s in multiple genes in both pathways
ensures a new and comprehensive coverage of common
genetic variation in the candidate genes. A detection of
heterogeneity in the treatment benefit according to genetic
determinants may lead to significant advances in tailored-
therapy and personalized medicine (Appendix).
Methods
Study population and design
The PERGENE study is a substudy of the EUROPA-trial
that will investigate genetic determinants of the treatment
effect of ACE-inhibition in all subjects (Fig. 1). The study
design of the EUROPA trial has been described in detail
elsewhere [24]. In short, the EUROPA-trial was a random-
ized, double-blind, placebo-controlled clinical trial, with
12,218 patients who were randomized after a 4-week run-in
period. Mean follow-up was 4.2 years. The study recruited
men and women aged ≥18 years without clinical evidence
of heart failure and with evidence of coronary artery disease
documented by either previous MI, percutaneous or surgical
coronary revascularization or angiographic evidence of ≥70%
narrowing of ≥1major coronary artery.Menwere also recruited
if they had a history of chest pain and a positive exercise test or
regional wall motion abnormalities during stress echocardiog-
raphy or nuclear scintigraphy or with transient perfusion
defects during scintigraphy perfusion imaging.
The EUROPA study comprised a run-in period of
2 weeks during which patients received perindopril 4 mg/
day, followed by 2 weeks during which patients received
perindopril 8 mg/day provided that the 4 mg/day of
perindopril was well tolerated. At the end of the run-in
period, a double-blind treatment period of at least 36 months
started during which patients received either perindopril
8 mg/day or placebo. Patients continued in the study until
the last patient included completed the follow-up period.
Following randomization, patients were seen at 3, 6 and
12 months and thereafter at six monthly intervals. Written
informed consent was obtained from all patients for
performing genetic association analyses.
Outcome measures
The main outcome measure of PERGENE is to assess (1)
the effect of RAAS and bradykinin polymorphisms on the
risk reduction of the primary endpoint of EUROPA
(cardiovascular mortality, non-fatal MI, or successful
resuscitated cardiac arrest) by perindopril. Other outcome
measures are: (2) the effect of RAAS- and bradykinin
polymorphisms on the amount of blood pressure reduction
by perindopril treatment during the run-in period (in which
all patient were treated with perindopril), (3) the effect of
RAAS- and bradykinin polymorphisms on blood pressure,
(4) the effect of RAAS- and bradykinin polymorphisms on
incident cardiovascular risk during 4 years follow-up, and
(5) the effect of RAAS- and bradykinin polymorphisms in
relation to intolerance of ACE-inhibitors (Table 1). Other
relevant hypotheses can be investigated in the future.
Data collection
Large scale blood sample collection (Fig. 1)
A logistic procedure and a high-quality program for the
creation of a DNA bio-bank was established within the
EUROPA trial [25]. Our group defined a successful protocol
for large-scale blood samples collection in a large multi-
centre clinical trial. Blood sample were sent to a central
laboratory (TNO Leiden, The Netherlands), registered,
labeled and erythrocytes were lyzed. Buffy coats were frozen
at −40°C in three aliquots. A total of 10,497 blood tubes of
participants of the EUROPA-trial were received at the central
core laboratory for storage. The average time between blood
collection and processing was 10.1 (SD 8.4) days. The effect
of transport time in the EUROPA trial was validated and
shown to have no major effect on the DNA quality and
quantity in a selection of 61 blood samples representing a
wide range of transport times and countries. In all cases,
sufficient amounts of DNA could be isolated and obtained
from all samples; there was no relation with the region of
origin, or with varying environmental temperatures, and the
amount of DNA isolated. The quality and quantity of the
DNA was high and well suited for performing genetic
association studies [25].
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DNA isolation
DNA was isolated from the stored white blood cells at the
Genetic Laboratory of the department of Internal Medicine
at the Erasmus MC using an automated isolation process
(Hamilton liquid handler coupled with Magnetic separator
for automated DNA extraction). The isolated DNA was
stored in matrix 2D tubes and normalized and reformatted,
using a pipetting robot, and dispensed into 384-well PCR
plates using a Caliper Sciclone ALH3000 pipetting robot
(Caliper LS, Mountain View, CA),
Candidate genes
The candidate genes to be studied are located in the RAAS
and bradykinin pathways as presented in Fig. 2. ACE-
inhibitors inhibit the angiotensin-converting enzyme, which
is a central component of the RAAS and genes in this
pathway are therefore highly relevant to be studied with
respect to treatment effect of ACE-inhibitors. Candidate
genes are ACE, angiotensinogen (AGT) and the angioten-
sin II receptor type 1 and type 2 gene (AGTR1, AGTR2).
Also, several new and relatively unexplored genes in this
pathway are of interest to investigate pharmaco-genetically,
such as the renin (REN) and aldosterone synthase genes
(CYP11b2). Moreover, as ACE cleaves bradykinin into
inactive peptides, ACE-inhibitors increase bradykinin,
which, amongst others, results in anti-remodeling, anti-
atherosclerotic and anti-thrombotic effects, improves endo-
thelial function and is also a strong vasodilator. As such,
bradykinin counteracts the effect of angiotensin II in many
ways. This pathway has not been explored yet with respect
to pharmacogenetics, but may be very interesting, especial-
ly since the blood pressure effect and clinical effect of
ACE-inhibitors are likely to be caused by bradykinin [26].
Relevant genes in this pathway are kallikrein (KLK),
kininogen (KNG), and bradykinin-receptors (BDKRB 1
and 2), and the resultant endothelial nitric oxide synthase
Fig. 1 Flow diagram of PERGENE study design. htSNP haplotype-tagging SNP
Table 1 Outcome measures of the PERGENE study
Endpoint definitions of PERGENE
The effect of genetic factors on the treatment effect by perindoprila
The effect of genetic factors on blood pressure reduction levels by ACE-inhibition
The effect of genetic factors in relation to baseline hypertensionb
The effect of genetic factors on incident cardiovascular risk during 4 years of follow-up.
The effect of genetic factors on side-effects or intolerance during ACE-inhibitor treatment
a Defined as the reduction in the primary endpoint of the EUROPA-trial (cardiovascular mortality, non-fatal MI, or successfully resuscitated
cardiac arrest)
b Pre-defined in the EUROPA study protocol as a systolic blood pressure ≥160 mmHg and/or use of antihypertensives
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genes (eNOS3). This list of candidate genes ensures a
comprehensive coverage of relevant genes in the RAAS
and bradykinin pathways, which have not been investigated
to this extent in prior studies.
Selection of single nucleotide polymorphisms (SNPs)
To cover the genetic variation in these candidate genes
more comprehensively, the list of selected polymorphisms
in the candidate genes were selected using the latest
genetic information from available databases (such as
dbSNP: http://www.ncbi.nlm.nih.gov/SNP and Celera
http://www.celeradiscoverysystem.com) and our own re-
search (WAVE dHPLC; sequencing). The final selection
will also take into account the haplotype block structure of
these SNPs by using HapMap data (HapMap Release 23a/
Phase II Mar 08/on NCBI B36 assembly/ DbSNP b126),
and SeattleSNP databases (see: http://hapmap.jst.go.jp/
index.html and http://pga.gs.washington.edu), as well as
Ensemble and OMIM. Tagging SNP’s are representative
SNP’s in a region of the gene with high linkage
disequilibrium, which makes it possible to identify genetic
variation without genotyping every SNP within the gene
and reach a high coverage of common variation within the
gene with a limited number of tagging SNP’s. Linkage
disequilibrium, as provided by the HapMap project, is a
measure of the non-random association between poly-
morphisms at different loci and it describes a situation in
which some combinations of alleles or genetic markers
occur with a higher or lower frequency in a population
than would be expected from a random formation of
haplotypes from alleles based on their frequencies. We
selected tagging SNP’s are within the candidate genes
using Caucasian subjects as reference population since in
the EUROPA-trial more than 99% of the patients were
of Caucasian origin. In Haploview, we will use a cut-off of
minor allele frequency of 5% and haplotype frequency of
5% with r2 of 0.80 to select the haplotype tagging SNP’s
within the candidate genes and aim to achieve more than
90% coverage of common genetic variation. The selected
area of the gene always should contain about 2 kb at the 5′
and 3′ ends of the gene to ensure maximum coverage of
functionally relevant genetic areas. In selecting these
haplotype-tagging SNP’s, we prefer to use functional
SNP’s or SNP’s located in regulatory or promoter regions
of the gene. In addition, we will add several relevant
SNP’s to our list based on prior literature.
Genotyping
We will use a high-throughput genotyping facility including
a Caliper Sciclone ALH 3000 pipetting robot (including a
TwisterII, and integrated plate sealer, plate reader (OD260/
280)), and polymerase-chain-reaction (PCR) machine (ABI
Fig. 2 Selected candidate genes in the renin–angiotensin–aldosteron-
system and bradykinin pathways. The arrows with a plus mark
correspond to a stimulatory effect and arrows with a minus mark to a
inhibitory effect. To the left and right is a list of candidate genes
attached at each corresponding level within the RAAS and bradykinin
pathways. AGT angiotensinogen, REN renin, ACE angiotensin-
converting enzyme, AGTR1 angiotensin II receptor type 1, AGTR2
angiotensin II receptor type 2, CYP11B aldosteron synthase, KLK
kallikrein, KNG kininogen, BDKRB1 bradykinin receptor type 1,
BDKRB2 bradykinin receptor type 2, eNOS3 nitric oxide synthase
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9700, 2×384)), an ABI7900HT Taqman (running 2 ng
gDNA in 2 μL reactions). The most commonly used
genotyping techniques are Taqman (for one to ten SNP’s)
and Sequenom (for five to 40 SNP’s).
Allelic discrimination with Taqman
Genotypes will be determined in genomic DNA with the
Taqman allelic discrimination assay (Applied Biosystems,
Foster City, CA, USA). Assay-by-Design service (http://
www.appliedbio-systems.com) will be used to set up a
TaqMan allelic discrimination assay for the selected SNP’s;
primer designs are readily available at ABI. The PCR
mixture includes 1–2 ng genomic DNA in a 2-μl volume
and the following reagents: probes (200 nM), primers
(0.9 μM), 2× Taqman PCR master mix (AB gene, or ABI).
Reagents are dispensed in a 384-well plate using the Deerac
Equator NS808 (Deerac Fluidics, Dublin, Ireland). PCR
cycling reactions will be performed in 384-well PCR plates
in an ABI 9700 PCR system (Applied Biosystems Inc.,
Foster City, CA). These consist of initial denaturation for
15 min at 95°C and 40 cycles with denaturation for 15 s at
95°C and annealing and extension for 60 s at 60°C. Allele-
specific fluorescence was then analyzed on an ABI Prism
7900HT Sequence Detection System with SDS v 2.1 (Applied
Biosystems) and results analyzed by the ABI TaqMan 7900HT
using the sequence detection system 2.22 software (Applied
Biosystems). To confirm the accuracy of the genotyping, 5%
randomly selected samples and duplicates will be included and
genotyped additionally in the same procedure.
Mass-spectrometric genotyping
Polymerase-chain-reaction (PCR) assays and extension
primers for these SNP’s are designed with the use of
MassARRAY software, version 3.0 (Sequenom). The
MassARRAY Designer software can automatically design
both PCR and MassEXTEND primers for multiplexed
assays. MassEXTEND is a primer extension process
designed to detect sequence differences at the single
nucleotide level. The primer is extended, dependent upon
the template sequence, resulting in an allele-specific
difference in mass between extension products. This mass
difference allows the data analysis software to differentiate
between SNP alleles. PCR and extension reactions will be
performed according to the manufacturer's instructions, and
extension product sizes determined by mass spectrometry
(Sequenom). The iPLEX Gold assay uses a single termina-
tion mix and universal reaction conditions for all SNP’s.
The SpectroCHIP arrays are placed into the MALDI-TOF
mass spectrometer and the mass correlating genotype is
determined in real time. Duplicate test samples (control
plates, 5%) and six water samples per plate (PCR-negative
controls), of which the technician is unaware, are included
in each 96-well plate. The rate of concordant results
between duplicate samples will be checked.
Quality control for the genotyping will further involve
testing for Hardy–Weinberg equilibrium and repeated
laboratory analyses in a random group of samples. To
ensure high-quality output of SNP, eg. if the call rate or
clustering was difficult, the SNP can be tested with
alternative approaches (e.g. Taqman reaction mixtures) or
on the other genotyping platform (Sequenom) likewise.
Data analysis
Statistical analysis and statistical power
In the EUROPA study, 9% of patients (n=1091) had a major
cardiovascular event during follow-up (cardiovascular death,
MI, cardiac arrest: 603 (10%) placebo and 488 (8%), 20%
relative risk reduction (95% CI 9–29, p=0.0003). A
secondary endpoint (total mortality, non-fatal MI, hospital
admission for UAP, cardiac arrest) occurred in 16% of
patients (n=1,947). Event rates will be compared between
treatment groups and the treatment effect will be compared
between genotype strata (for each gene). Gene–drug interac-
tion for relative risk reductions will be assessed using Cox
proportional hazards regression analysis. Hardy–Weinberg
equilibrium of each polymorphism will be tested using
Chi-square analysis. All analyses will be based on intention
to treat. A p-value of 0.05 or less will be deemed significant.
Haplotype analysis
Haplotypes will be inferred with use of the program Haplo.
Stats and R. Haplotype alleles present in the patient
population were inferred by means of the haplo.em function
of the program Haplo Stats (http://cran.r-project.org/src/
contrib/Descriptions/haplo.stats.html), which computes
maximum likelihood estimates of haplotype probabilities.
Sample size considerations
The large study size and large number of events (n>1,000)
will provide sufficient power for the detection of interaction
effects. The size of this pharmacogenetic substudy allows
detection with a power of 98% to detect a difference in
hazard ratios (treatment effect for the primary endpoint) of
20% between genotypes with minor allele frequency of 0.20,
based upon ten-thousand patients (two-sided alpha 0.05). For
other genotype distributions, power will be less but for most
comparisons still above 80%. For a minor allele frequency of
0.10, statistical power is 88% to detect a difference in
treatment effect of 20% with a two-sided alpha 0.05 (Fig. 3).
176 Cardiovasc Drugs Ther (2009) 23:171–181
Discussion
In European countries and in other countries worldwide,
millions of patients have coronary artery disease, and are at
risk of (recurrent) events, particularly cardiovascular death
and myocardial infarction. The ACE-inhibitors are among
one of the most frequently prescribed drugs for secondary
prevention in patients with stable coronary artery disease.
Still, in the secondary prevention setting, there are no means
of guiding therapy to those patients who are most likely to
benefit. Prior attempts to target ACE-inhibitors have not
been successful, largely due to because of the consistency in
the treatment effect in clinical subgroups [19–21].
In the EUROPA study, treatment with perindopril in 50
patients for a period of 4 years (200 patient years) was
required to prevent one major cardiovascular event. The
efficiency, and the cost-effectiveness of such prolonged
prophylactic treatment would be significantly enhanced if
patients who do benefit and those who do not benefit from
an ACE-inhibitor could be distinguished prior to the start of
treatment. For this purpose, it is important to study possible
heterogeneities in the treatment effect to assess whether a
variation in the treatment effect does exist which then can
be used to guide ACE-inhibitor therapy to the patients most
likely to benefit of treatment.
There are several arguments that this variation in
treatment effect may indeed exist. For instance, the activity
of ACE and angiotensinogen (plasma levels) have been
shown to vary widely between patients, also in the response
to an ACE-inhibitor [17]. Also, a large inter-individual
variability in blood pressure response to ACE inhibition is
well documented. Whether the treatment effect on outcome
reduction varies in a similar way is unknown. Until now
subgroup analysis based on clinical characteristics has
resulted in consistent treatment effects [19–21]. Still,
relative and absolute risk reductions with ACE inhibitor
therapy vary. A larger risk reduction is seen in heart failure
patients as compared to coronary artery disease patients [19].
Therefore it is likely that the treatment effect of ACE-
inhibitor use on outcome (in CAD patients) will also differ,
some patients will benefit others will not. The integration of
genetic information, which is highly specific for each
individual patient, can be a new way to identify a true
heterogeneity in the treatment effect of ACE-inhibitors. A
pharmacogenetic profile related to drug response can be
used to target ACE-inhibitors to those patients most likely
to benefit of treatment.
It has been suggested that the response to drug therapy
may be influenced by genetic polymorphisms in different
ways. Firstly, variations within genes of the RAAS and
related systems may influence the disease process (athero-
sclerosis) and inherent differences in accessibility to
therapeutic agents such as ACE-inhibitors. Secondly,
pharmacodynamics may be affected by polymorphisms
in the genes of all proteins involved in the RAAS and
related systems, including receptors and signal transduc-
tion molecules. Thirdly, variations in drug absorption and
metabolic clearance may cause inter-individual variation
in pharmacokinetics.
Genetic polymorphisms in the ACE and AGT genes have
been shown to influence plasma levels of these enzymes,
mainly M235T and T174M in AGT and ACE I/D in ACE
[27]. For example with the M235T polymorphism, the
TT-allele results in higher levels of angiotensinogen.
Regarding intermediate endpoints, a series of relatively
small studies (34 to 345 patients) reported that poly-
morphisms in the ACE, angiotensinogen and AGTR1 and
AGTR2 genes modulated the effects of ACE-inhibitors
[28]. Such interactions were shown for specific alleles in
relation with blood pressure reduction, regression of left
ventricular hypertrophy, diastolic cardiac function and re-
stenosis after percutaneous coronary intervention.
Regarding outcomes, pharmacogenetic data is very
scarce. The PROGRESS study, which included 5,688
patients with history of stroke, did not show an association
of the ACE I/D polymorphism and ACE-inhibition on risk
reduction of cerebrovascular events [29]. The inconsistency
in these studies could be explained by the fact that in
virtually all association studies only one RAAS gene was
taken into consideration, thereby ignoring the well-docu-
mented feedback mechanisms within the RAAS [30]. For
instance, the elevated angiotensinogen levels which are
found in Thr235 homozygotes are accompanied by reduced
renin levels, so that the angiotensin I-generating capacity
returns to normal in those with high angiotensinogen
concentrations. In addition, the two angiotensin II receptors
(AT1 and AT2) that exist in humans have counteracting
effects [31, 32]. Thus, future studies should preferably
investigate more than one RAAS gene (and ideally all
genes: renin, angiotensinogen, ACE, AGTR1, AGTR2,
aldosterone synthase).
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Fig. 3 Power estimations for PERGENE. The Y-axis corresponds to
the power (0–100%) and the X-axis to the Odds Ration (1.0–2.0), the
coloured lines correspond to the minor allele frequencies of SNP’s
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The DNA samples collected in the EUROPA study offer
a unique opportunity to investigate the relations between
polymorphisms in genes of the RAAS with the treatment
benefit of an ACE inhibitor on cardiovascular events in a
sufficiently large population and in a randomized double-
blind setting. As mentioned, the available studies of this
subject have been of small size, not randomized and
therefore, reported relationships may have been due to
chance findings. Furthermore, the majority of studies so far
included only one polymorphism or one gene of the RAAS.
In contrast, the PERGENE study uses a haplotype
tagging selection procedure to comprehensively cover all
common genetic variations (>90%) in the relevant genes
within the RAAS and bradykinin pathways. We will use the
latest information from HapMap Genome project, SEAT-
TLE and other up to date genetic information platforms as
well as sophisticated software packages as Haplostats and R
for these haplotype analyses.
Haplotypes are a combination of alleles at different markers
along the same chromosome that are inherited as a unit
(linkage disequilibrium-patterns). The determination of hap-
lotypes is essential for understanding genetic variation and the
inheritance of complex diseases. An analysis based on
haplotypes is advantageous over an analysis based on
individual SNPs, especially in the presence of multiple
susceptibility alleles, and when linkage disequilibria between
SNPs are weak. With a single SNP approach, associations
may be missed when the causal SNP is not in linkage
disequilibrium with the single analyzed SNP. It is more
informative to simultaneously analyze multiple markers in a
region of interest that identifies genetic variants underlying
various human traits; Also, these markers should be selected
based on tagging principles and linkage disequilibrium. By
combining information frommultiple SNP’s in the RAAS and
bradykinin pathway genes, a more efficient and comprehen-
sive in-depth analysis of common genetic variation in relation
to ACE-inhibitor therapy is performed, which is more likely to
unravel any important pharmacogenetic associations.
In summary, this project is unique because of its size,
design (randomized-setting), accurate phenotypic data, com-
plete coverage of two pathways (RAAS and bradykinin), but
also because of the extensive and comprehensive SNP
selection procedure which involves multiple SNP in multiple
genes of both pathways with integrating information on the
haplotype structure of RAAS and bradykinin genes.
Until now, attempts to target therapy using simple
clinical patient characteristics have been insufficient to
guide ACE-inhibition therapy and it is not yet possible to
say in advance who to treat or not [19–21]. New and
improved approaches that integrate more patient-specific
characteristics are needed to target ACE-inhibitor therapy.
We will investigate whether specific genetic polymorphisms
in RAAS genes modify the treatment effect of ACE-inhibitor
therapy. Our aim is to develop a pharmacogenetic profile
associated with the benefit of ACE inhibitor therapy in
patients with stable coronary artery disease.
If it is possible to construct a pharmacogenetic profile related
to treatment benefit, this could lead to a significant reduction of
the number of patients needed to treat. It should be realized in
this regard that the absolute treatment effects are only modest
(about 2% absolute risk reduction) in stable CAD patients.
In the EUROPA trial, 200 patient years of treatment with
perindopril 8 mg was necessary to prevent one event in the
primary endpoint (number needed to treat 50 for 4 years)
[7, 33]. A pharmaco-genetic profile related to the benefit of
perindopril may enable the selection of those patients
advance of treatment. Likewise, targeting therapy to only
those patients that are to benefit will considerably increase
the cost-effectiveness of treatment. Until now, cardiovascu-
lar pharmacogenetic research is still in a premature stage
but has the potential to enhance personalized medicine and
tailored-therapy in cardiovascular medicine.
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